SD-SAB-BIO/CSL-BEHRING
7.1.2020 15:38:13 CET | Business Wire | Press release
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, today announced that it has entered into multiple collaboration and option agreements with global biotherapeutics leader CSL Behring. The collaborations will explore the possibility and the potential of new therapies to treat challenging autoimmune, infectious and idiopathic diseases by leveraging SAB’s DiversitAb™ platform.
SAB has developed a unique platform, through advanced genetic engineering, to naturally and rapidly produce large amounts of human antibodies without using human donors.
The agreement includes a research program which will investigate a potential new source for human immunoglobulin G (IgG). Human IgG is currently used for a number of immunological and neurological diseases including Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), and Multifocal Motor Neuropathy (MMN).
CSL Behring is a leader in the global immunoglobulins market, which has grown substantially over the last five years. Key factors fueling market growth include an aging population, increased emphasis on the diagnosis and treatment of immune diseases, and its increased use in new indications.
“SAB Biotherapeutics has developed a very interesting and novel platform for the production of human immunoglobulins,” said Dr. Andrew Nash, Senior Vice President, Research for CSL Behring. “CSL Behring is committed to the continuous development of innovative therapies that address unmet needs for patients with rare and serious diseases. This collaboration will provide both companies an opportunity to explore the potential of these new approaches to positively impact areas of need.”
CSL Behring’s R&D footprint includes more than 1,700 scientists across the globe with an R&D investment exceeding $800 million in 2018 - 2019.
“We are excited that CSL Behring has chosen to work with SAB Biotherapeutics to explore new immunotherapies leveraging our technology platform,” said Dr. Eddie J. Sullivan, president, CEO and co-founder of SAB Biotherapeutics. “We believe combining our unique human antibody development and production capabilities with CSL Behring’s established immunoglobulin franchise and vast expertise in biopharmaceutical development will broaden therapeutic possibilities.”
CSL Behring and SAB will share research program and related costs and plan to complete the initial phase in 2020. The collaboration may lead to subsequent development and commercialization agreements.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB), headquartered in Sioux Falls, S.D. is a clinical-stage, biopharmaceutical development company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. Utilizing some of the most complex genetic engineering and antibody science in the world, SAB has developed the only platform that can rapidly produce natural, highly targeted, high-potency, immunotherapies at commercial scale. The company is advancing programs in autoimmunity, infectious diseases, inflammation and exploratory oncology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005718/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Delivers Solid 9 Months & Q3 2026 Results and Reiterates Full-Year Outlook5.11.2026 10:22:00 CET | Press release
SES S.A. announces financial results for the nine and three months ended September 30, 2026. YTD 2026 Performance (€ million) YTD 2026 as reported (1) YTD 2025 as reported (1)(5) ∆ At constant FX (2) YTD 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.16 1.11 1.11 Revenue 2,472 1,743 +45.5% 2,628 -2.0% Adjusted EBITDA (4) 1,138 838 +40.0% 1,170 +1.4% 1) ‘Reported basis’ with Intelsat fully consolidated from July 17, 2025 2) ‘At constant FX’ refers to comparative figures restated at the current period FX rates to neutralize currency variations 3) ‘Like-for-like basis’ is as if Intelsat was fully consolidated from January 1, 2024 4) Excluding operating expenses/income recognized in relation to U.S. C-band repurposing, other income non-recurring, fair value movement on contingent value rights and other significant special items (disclosed separately) 5) 2025 has been restated to reflect Purchase Price Allocation (PPA) adjustments recorded in connection with the acquisitio
I’m green™ bio-based Polyethylene, Produced From Sugarcane-Derived Renewable Feedstock, Incorporated Into Mondi’s Flexible Pouch5.11.2026 10:17:00 CET | Press release
At Interpack 2026, I’m green™ bio-based and Mondi presented a forward-thinking approach to flexible packaging, combining renewable material innovation with process simplicity to reduce environmental impact without compromising functionality. Renewable materials meet flexible packaging At the heart of the solution is Mondi’s re/cycle StripPouch, made with at least 98% I’m green™ bio-based polyethylene derived from renewable sugarcane, offering an alternative to conventional fossil-based materials. By integrating I’m green™ bio-based polyethylene into the design, the collaboration demonstrates the potential to expand the use of bio-based materials in high-performance applications such as food, home and personal care packaging. The pouch also incorporates laser-marking technology during the converting process, eliminating the need for inks and additional processing steps. This not only simplifies the packaging design but also contributes to faster artwork changes, greater personalisation
Diplomacy, Business, Innovation : SIAL Paris 2026 at the Heart of Global Food Challenges5.11.2026 10:00:00 CET | Press release
305,000 professionals, 8,000 exhibitors and 192 countries and regions represented: SIAL Paris reaffirms its role as a global platform for influence, business and food innovation. Held under the High Patronage of the President of the French Republic, SIAL Paris closed its doors on October 21 after five days that made Paris the centre of gravity for the global food industry. A meeting of G7 Agriculture Ministers, India as Country of Honour and food sovereignty were among the defining highlights of this edition. SIAL Paris, where nations come together Against a backdrop of geopolitical tensions and shifting international trade dynamics, SIAL Paris reinforced its role as a platform for international dialogue. On October 19, a high-level meeting dedicated to food security and sovereignty brought together Agriculture Ministers and G7 representatives, alongside European Commissioner Christophe Hansen. More than 100 diplomatic and international delegations attended the event. This internationa
Festo, Softcat, ANS Group and SCC Demonstrate the Business Impact of AI-Powered Observability5.11.2026 09:00:00 CET | Press release
LogicMonitor's 2026 EMEA Elevate Award winners are reducing alert noise, accelerating incident detection and transforming IT operations with AI and automation LogicMonitor®, the AI-first platform for Autonomous IT, announced the 2026 Elevate Award winners today at its Elevate Community Conference in London. The annual awards recognize LogicMonitor customers and partners that are achieving measurable business and operational outcomes through AI-powered observability. From consolidating 90% of monitoring tools and reducing alert noise by 85% to cutting observability case volumes by 45%, this year's EMEA winners demonstrate how organizations are simplifying complex IT environments, improving resilience and putting AI-powered operations into practice. “This year's EMEA Elevate Award winners are proving that the path to Autonomous IT starts with real, measurable improvements in how organizations operate,” said John Grosshans, President of Field Operations, LogicMonitor. “They're reducing co
New AGCO Power CORE Engines to Power Two New Tractors at EIMA 20265.11.2026 07:00:00 CET | Press release
AGCO Power’s CORE engine technology will be represented at EIMA International 2026 in new tractors from Massey Ferguson and Valtra. Developed from a clean sheet, the CORE engine family provides a next-generation platform for demanding off-highway applications. At EIMA International in Bologna, Italy, on November 10–14, 2026, visitors will be able to see how the AGCO Power CORE75 engine platform supports the different requirements of the Massey Ferguson new model MF 7S MARK 2 range and Valtra’s new sixth-generation Valtra T Series. A CORE75 engine will also be on display at the Valtra stand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104588496/en/ Massey Ferguson 7S MARK 2 The CORE engine family represents AGCO Power’s investment in a completely new engine platform at a time when few manufacturers are making comparable commitments to off-highway combustion engine development. The CORE engine family is designed to meet
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom